Legal

1. Who’s Who in the BATWatch™ Program

These BAT Testing™ Terms apply to all BAT Testing™ services offered through the BATWatch™ platform.

BATWatch refers collectively to a network of affiliated legal entities and coordination systems, including:

BATWatch Medical Group, LLC – A national management services organization (MSO) that provides infrastructure, coordination protocols, digital tools, and operational oversight to support early brain health monitoring and intervention.

Affiliated Professional Corporations (PCs) – State-licensed entities operating under the BATWatch name (e.g., BATWatch of California, PC) responsible for delivering clinical services and telehealth care, where licensed.

BATWatch Provider Network – Licensed, independent providers who engage in testing, biological review, or care coordination under the BATWatch protocol.

Silver House Technologies, Inc. – The parent company and intellectual property owner that created and licenses the BATWatch platform, scoring systems, and drift-tracking frameworks. Silver House does not deliver clinical services or act as a healthcare provider.

Unless otherwise noted, references to “BATWatch” in this document refer collectively to the ecosystem above, functioning within each entity’s defined legal and operational scope.

2. Key Definition
• BAT Testing™: A structured, multi-step blood-based lab sequence used to detect Beta-Amyloid and Tau accumulation and monitor biological drift.
• BAT Levels™: Blood-based markers (BA + Tau) that reflect early brain health disruption—prior to clinical symptoms.
• BATScore™: A 0–100 scale measuring the biological burden of BAT Levels and related systems. 100 is optimal. Below 100 means drift is occurring.
• BAT Pill Protocol™: A short, cycle-based intervention using off-label Sirolimus to stimulate autophagy and reduce BAT Levels.
• ClearCheck™ Panel: The final test sequence after the BAT Pill Protocol to confirm clearance and detect any rebound.
• Contribution Factor Mapping (CFM): The pre-test screening that stratifies patients based on lifestyle, inflammation, and other known contributors to brain drift.
• Mechanism Mapping™ (MM Panel): A deep lab panel that analyzes inflammation, glymphatic clearance, mitochondrial function, and hormone/metabolic dysfunction.
• Referring Provider: Any external clinician referring a patient for BAT Testing™. They may receive summaries but are not required to manage treatment.
• Patient: Any individual who registers for or completes BAT Testing™.

3. Stepwise Testing Protocol
BAT Testing is not a single blood test. It’s a structured process with multiple checkpoints designed to reduce false positives, avoid overreaction, and guide smarter intervention when necessary.

Here’s how it works:

1. Step 1: BA Test (Beta-Amyloid)
This is the foundational test. It measures plasma 42/40 ratio and detects early beta-amyloid accumulation.

2. Step 2: Reflex Testing
Based on Step 1, one of the following will be initiated:
o A second BA Test to confirm results (especially if insurance requires more evidence).
o An FC Panel (Factor Check), which includes BA retest + Tau + Glymphatic Risk Test (GRT), used to confirm drift and stratify biological risk.

3. Step 3: Pre-Cycle Coordination
If results show elevated BAT Levels and risk is confirmed, patients are invited to begin the BAT Pill Protocol. Before starting, we run the CheckPoint (CP) Panel to evaluate readiness and safety.

4. Step 4: Post-Cycle Testing
After treatment, we run the ClearCheck™ (CC) and Mechanism Mapping (MM) panels to:
o Confirm that BAT Levels have dropped.
o Understand why drift happened.
o Guide long-term follow-up and prevention.

4. Why One Test Isn’t Enough
Beta-Amyloid fluctuates. So does Tau.
They can be influenced by:
• Sleep
• Inflammation
• Stress
• Sample handling

That’s why BATWatch never makes decisions based on one test alone. We use:
• Reflex testing to double-check.
• Confirmation panels to validate biological risk.
• Multi-test sequences to ensure we’re seeing a true pattern—not a temporary blip.

This approach helps reduce false positives and false negatives—and ensures confidence before any intervention is considered.

5. Why Blood Testing Makes More Sense Than a Spinal Tap

Spinal taps aren’t more accurate… they’re just more invasive.

Here’s what most people don’t realize:
• CSF biomarkers fluctuate the same way plasma biomarkers do.
• You’d need multiple spinal taps to establish a reliable trend.
• No patient wants that. Especially not for prevention.

Modern blood-based tests now show AUCs over 0.90, with strong correlation to CSF findings. That’s why we choose blood:
• It’s scalable, repeatable, and safer.
• It allows annual tracking… like A1C or cholesterol.
• It gives patients early insight, without needing sedation or hospitalization.

Prevention doesn’t require pain. And now, it doesn’t require spinal taps either.

6. Insurance, Lab Partners & Financial Access
• Some tests are covered by insurance. Others may require pre-authorization.
• We handle all insurance submission and appeals.
• If a test is denied or partially covered, cash-pay options and financial assistance are available through our lab partners.
• BATWatch does not sell or profit from the labs themselves. We’re test-agnostic. Labs must simply meet our accuracy, reproducibility, and analyte thresholds.

7. Your Results, Our Responsibilities
a) Data Custodian

BATWatch™ serves as the designated custodian of all patient medical records associated with BAT Testing™, including lab results, interpretations, and related treatment recommendations. All data is securely maintained in compliance with HIPAA and applicable state or international data privacy laws.

b) Results Access

Patients receive secure digital access to their testing results and progress updates via the BATWatch platform. Authorized referring providers and participating clinicians within the BATWatch Network may be granted access based on patient consent and data-sharing preferences.

c) Shared Access with Referring Providers

If a licensed provider initiated the BAT Testing™ process or is affiliated with BATWatch, that provider may receive lab summaries, biomarker reports, and care coordination notes. Clinical decision-making and protocol execution remain under BATWatch’s centralized care model unless explicitly delegated.

d) Research & Quality Improvement

De-identified data may be used for research, clinical quality improvement, and protocol optimization in accordance with BATWatch’s Privacy Policies. No identifiable data will be used without explicit, written authorization from the patient.

e) Record Retention
All medical records, including lab reports, scoring history, and treatment logs, are retained in accordance with federal recordkeeping standards and research documentation requirements.

For more information about how your data is used, shared, and protected, please refer to our official Notice of Privacy Practices.